Skip Nav Destination
1-4 of 4
Abhishek Maiti, Miguel J. Franquiz, Farhad Ravandi, Jorge E. Cortes, Elias J. Jabbour, Koji Sasaki, Kayleigh Marx, Naval G. Daver, Tapan M. Kadia, Marina Y. Konopleva, Lucia Masarova, Gautam Borthakur, Courtney D. DiNardo, Kiran Naqvi, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short
Acta Haematol (2020) 143 (6): 567–573.
Published Online: 09 February 2021
... of prior therapy cycles was 5 (range 2–8). Nine patients received decitabine-based, and 7 received intensive chemotherapy-based regimens. Ten patients (63%) received ponatinib. The overall response rate (ORR) in 15 evaluable patients was 60% (1 complete remission [CR], 6 CR with incomplete hematologic...
Selena Zhou, Douglas Tremblay, Ronald Hoffman, Marina Kremyanskaya, Vesna Najfeld, Lihua Li, Erin Moshier, John Mascarenhas
Acta Haematol (2021) 144 (1): 48–57.
Published Online: 11 March 2020
...Selena Zhou; Douglas Tremblay; Ronald Hoffman; Marina Kremyanskaya; Vesna Najfeld; Lihua Li; Erin Moshier; John Mascarenhas Treatment options are limited for patients with advanced forms of myeloproliferative neoplasms (MPN) including blast-phase disease (MPN-BP). Decitabine has frequently been...
Hongmin Li, Liru Wang, Yue Wu, Li Su, Hong Zhao, Yongqing Zhang, Zhao Wang, Dayong Huang, Zhongxia Huang, Xiaoxiong Wu, Xiaohong Li, Fang Ye, Fan Yu, Hui Liu, Jing-Wen Wang, Jia Cong, Wanjun Sun, Hui-Ren Chen, Jingbo Wang, Bing Han
Acta Haematol (2017) 138 (3): 168–174.
Published Online: 19 October 2017
...Hongmin Li; Liru Wang; Yue Wu; Li Su; Hong Zhao; Yongqing Zhang; Zhao Wang; Dayong Huang; Zhongxia Huang; Xiaoxiong Wu; Xiaohong Li; Fang Ye; Fan Yu; Hui Liu; Jing-Wen Wang; Jia Cong; Wanjun Sun; Hui-Ren Chen; Jingbo Wang; Bing Han Nowadays, the regular recommended dose of decitabine...
Acta Haematol (2017) 137 (4): 195–200.
Published Online: 27 April 2017
...Hongyu Zhao; Li Xu; Yongjian Yang; Jianhua Shao; Ping Chen; Xuebin Dong; Linping Gu; Daqi Li Aims: To investigate the safety and efficacy of the triple therapy of decitabine, idarubicin, and cytarabine in the treatment of refractory or recurrent acute myeloid leukemia (R/R AML). Methods: We...